| DUBLIN, Ireland, May 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that Dale Schenk, PhD, the Company`s President and Chief Executive Officer, will be presenting at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 8:00 AM ET. The conference will be held at The Grand Hyatt New York. |
A live webcast of the presentation can be accessed through the investor relations section of the Company`s website at www.prothena.com. Following the live presentation, a reply of the webcast will be available on the Company`s website for 90 days.
Prothena Corporation plc is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. These potential therapies have a number of indications, including AL and AA forms of amyloidosis (NEOD001), Parkinson`s disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in inflammatory diseases and metastatic cancers (PRX003). For more information, please visit www.prothena.com.
For more information, please visit the Company`s web site at www.prothena.com.
CONTACT: Investors: Tran Nguyen, CFO 650-837-8535, IR@prothena.com Media: Anita Kawatra 646-256-5116, firstname.lastname@example.org
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation via GlobeNewswire